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Background: High levels of emotional distress in cancer patients often goes unnoticed in daily clinical routine,
resulting in severe undertreatment of mental health problems in this patient group. Screening tools can be used
to increase case identification, however, screening alone does not necessarily translate into better mental health
for the patient. Doctors play a key role in providing basic emotional support and transferring the patients in need
of such specific support to mental health professionals. This study investigates whether a stepped care model,
combining screening, doctor consultation and professional psycho-oncological service in a structured way, improves
the emotional wellbeing of cancer patients.
Methods/Design: This study is a cluster randomized trial with two parallel groups (intervention vs. care as usual),
set in an academic hospital. Participants are cancer patients, a total of 1,000 at baseline. The intervention consists of
stepped psychosocial care. Step one: screening for distress, step two: feedback of screening results to the doctor in
charge of the patient and consultation with the patient, and step three: based on a shared patient-doctor decision,
either transferal to the consultation liaison (CL) service or not. The outcome will be emotional well-being half a year
after baseline, ascertained with the Hospital Anxiety and Depression Scale. Randomization will be done by the
cluster randomization of wards.
Discussion: Mental health problems not only cause emotional suffering but also direct and indirect costs. This calls
for timely and adequate psychosocial support, especially as we know that such support is effective. However, not
every cancer patient can and must be treated by a mental health professional. Allocating limited resources most
sensibly and economically is of crucial importance for our healthcare system to ensure the best quality of care to as
many patients as possible. It is the hope of the STEPPED CARE trial that this model is both effective and efficient,
and that it can be implemented in other hospitals as well, if proven to be effective.
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Psychosocial distress in cancer patients causes significant
financial and emotional costs. It is associated with high
utilization of health services, low quality of life and in-
creased mortality [1,2]. Meta-analyses show that one third
of all cancer patients in acute clinics suffer from severe
emotional distress and psychiatric comorbidity [3-5]. Un-
fortunately, such distress often goes undetected by health-
care providers, doctors and nurses alike [6-8]. This can
result in considerable undertreatment of mental health
problems [9]. Verdonck-de Leeuw et al. found in their
prospective study that only 21% of highly distressed can-
cer patients were referred to a psycho-oncologist or a
community worker [10]. We saw in one of our studies that
only 9% of those cancer patients with a comorbid mental
health condition were referred to a mental health special-
ist within three months of the diagnosis [11].
Such poor uptake of mental healthcare can only partly
be explained by patients’ denial of emotional problems or
hesitation to seek professional help. On the contrary, if pa-
tients are requested to indicate with whom they would like
to speak about their emotional problems, one third of pa-
tients express the wish to consult a psycho-oncologist,
and more than 80% request their physician [12].
It has been shown that if patients are asked to complete
a short questionnaire to report psychosocial problems,
under-diagnosis of poor mental health can be considerably
decreased [7,13,14]. However, better identification of dis-
tressed patients does not necessarily translate into better
patient care and, eventually, to improved mental health.
For example, implementing screening for depression into
the clinical routine did not improve mental health nor did
it reduce supportive care needs in a clinical trial [15], at
least not for the entire group of patients; only those with
medium or high levels of distress benefited from the
screening. Velikova et al. found in their three-arm trial
(arm one: screening and feedback to the physician; arm
two: screening only, no feedback and arm three: no
screening) that completing a questionnaire was the crucial
element for improving quality of life in cancer patients,
whereas the feedback to the physician improved mental
health [16].
It thus seems that patients’ mental health can be im-
proved by a smart combination of routine screening and
the involvement of healthcare professionals. It is the aim
of the current study to test the effect of such a health-
care model.
Aim and objectives
This study examines the effect of stepped psychosocial
care (screening, consultation with a doctor and referral
to psychosocial services) on mental health in cancer pa-
tients who are admitted for oncological treatment in a
hospital.The objectives are:
1. to determine the feasibility of integrating a new
strategy to detect and treat mental health problems
of cancer patients in different clinics and wards
(stepped care);
2. to investigate the effect of this new strategy (stepped
care) on patients’ mental health;
3. to examine the medium-term (six-month) effects of
the new strategy (stepped care).
The primary endpoint is patient-reported mental health.
Secondary endpoints are social functioning, psychiatric co-
morbidity, satisfaction with care and utilization of healthcare.
Methods/Design
Design
Experience from previous studies teaches us that investigat-
ing complex behavioral interventions with ‘simple’ random-
ized trials can create misleading results. If, for example,
students in a class are individually randomized to either be
trained to stop smoking or not, the outcome ‘change in fre-
quency of smoking’ will not entirely be related to the train-
ing itself. Students will talk to each other in the class, and,
especially if one of the informal leaders (‘opinion maker’) in
this class stops smoking, this will affect other students and
they will be more likely to stop smoking as well. From a
public health perspective, this is a most welcome effect.
Technically speaking, however, this is an undesired effect,
because it will blur the effects of the intervention; students
in the control group will show an effect as well. In other
words, individual randomization for the purpose of testing
behavioral interventions in larger groups will likely result
in an underestimation of the treatment effect. An alterna-
tive is the use of cluster randomization [17]. Here, clusters
of individuals are randomized rather than individuals
themselves, for example wards or clinics.
In our cluster randomized study, we randomized wards.
Two parallel groups are compared and the intervention is
expected to be superior to the control arm. The setting of
this study is an academic hospital: University Medical
Center Leipzig in Leipzig, Germany. Informed consent is
obtained from each study participant after admittance to
the ward, before the baseline assessment.
Intervention arm (arm one)
The intervention is a stepped care model to provide tar-
geted psychosocial help to cancer patients and consists
of three steps.
Step one: each patient is screened for distress. The re-
sults of this screening are electronically computed, graph-
ically visualized, and fed back to the clinician in charge.
Patients’ level of distress is visualized by colors analogue
to traffic lights: green = no or little distress, yellow =
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The doctor can also view the detailed numeric results.
Step two: if the patient is at a medium or high level of
distress, the doctor performs a brief interview along with
their routine consultation with this patient. Together,
they should discuss the psychosocial problems the pa-
tient currently has and decide on further steps. This sec-
ond step is a key element in the stepped care model. It
ensures the following: a) that the patients have access to
the doctor to discuss their emotional problems, which is
an important supportive care need for many patients
[18], b) ‘false positives’ can be detected early, c) the clin-
ician remains the key person for decisions on patient
care and d) the patients can express their needs or con-
cerns regarding psychosocial support. Studies show that
this procedure is well accepted by patients and physicians
[19,20]. As doctors frequently feel insufficiently prepared
to talk with patients about their emotional problems, and
sometimes avoid such consultations, they are trained indi-
vidually to perform this task. They learn how to, within
the limited consultation time, ask questions, respond to
patient concerns, consider their supportive care needs and
provide further help.
Step three: if the patient and doctor decide that psy-
chological support is needed, the hospital’s psycho-
oncological consultation liaison (CL) service is informed
and provides mental healthcare. If the patient has finan-
cial, vocational or other social problems, the hospital’s so-
cial service is called. If necessary, further support in the
outpatient setting when the patient is discharged from the
hospital is organized by these two teams.
Quality assurance: the team of this CL service consists
of psychologists with formal training in psychotherapy,
either cognitive-behavioral or psychodynamic. The social
services team consists of professionally trained social
workers. Both CL and social services provide support ac-
cording to the current guidelines. The psychotherapists
receive regular supervision by a fully trained senior psy-
chotherapist. Adherence to the stepped care model is
monitored by asking the patients whether their doctor
has discussed emotionally relevant topics.
Care as usual arm (arm two)
Patients who are treated on wards in the control arm re-
ceive care as usual. This means, doctors can call CL ser-
vice and the hospital’s social service whenever they feel
it is necessary. Doctors do not receive specific training
to detect distress or to talk with the patients about emo-
tional problems.
Data collection
The primary endpoint mental health is ascertained with
the Hospital Anxiety and Depression Scale (HADS) [21].
HADS identifies depressed patients with a sensitivity of0.96 [22]. Social problems are measured with the European
Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire Core Instrument (EORTC
QLQ-C30), using the social functioning and role function-
ing scales [23]. Satisfaction with care is measured with the
Quality of Care from the Patients Perspective question-
naire (QPP) [24], psychiatric comorbidity is measured
with the Structured Clinical Interview (SCID) [25]), and
the utilization of medical care is measured with the ques-
tionnaire used in the German Federal Health Survey [26].
Clinical data are obtained from the medical records. The
provision of CL services and/or social services is ascer-
tained from the hospital information system.
The patients are interviewed at the beginning (t1) and
the end (t2) of the hospital stay, three months after base-
line (t3) and six months after baseline (t4). At t1 and t2,
data collection is done electronically with the help of
tablet computers. At t3 and t4, it will be done via phone
or face-to-face, depending on the patient’s preference. For
patients who prefer paper-based data collection, this is
possible as well. The equivalence of both methods is
well documented [27,28,16]. The Computer-Based Health
Evaluation System (CHES) software (Evaluation Software
Development, Innsbruck, Austria) is employed for elec-
tronic data capture [29]. Electronic data capture ensures
that no missing data are in the data set unless the patient
quits the study. Study nurses with an academic psychology
education contact the patients, inform them about the
study, obtain written informed consent and perform data
collection. Patients in the control wards undergo the same
assessments as patients in the experimental wards.
Eligibility
Patients aged 18 years or older of both sexes and with
all types and stages of cancer are eligible for this study.
They must be admitted to the University Medical Center
Leipzig for diagnosis or treatment of cancer in one of the
following departments: Urology, Pneumology, Maxillofacial
Surgery, Radiation Oncology, Gynecology, Neurosurgery,
Visceral Surgery, Orthopedics, Gastroenterology, or Laryngo-
Rhino-Otology. Patient exclusion criteria are insufficient
command of German and no written informed consent.
Sample size
At the University Medical Center Leipzig, 2,000 patients
with malignant diseases are treated per year according
to the local cancer registry. Of those, about 350 are ineli-
gible for the study because of age or because they are
treated at a ward that is not participating in this study,
leaving 1,650 eligible patients per year and 137 per month.
Thus, about 1,200 patients can be approached initially.
Assuming that 20% of patients will decline participation
at t1, this leaves about 1,000 patients participating at
baseline. Based on previous experience from a large
Singer et al. Trials 2014, 15:482 Page 4 of 6
http://www.trialsjournal.com/content/15/1/482epidemiological study with cancer patients at the University
Medical Center Leipzig [22], we assumed that 20% of the
patients would drop out during the follow-up period due
to death or withdrawal from the study, leaving 800 pa-
tients at t4.
Cluster randomized trials must take into account the
within- and between-cluster variation by increasing the
sample size [30]. The between-cluster-variation coeffi-
cient could only be approximately estimated because of
a lack of data in the literature. We therefore used the
recommendation of Hayes and Bennett [30] and as-
sumed k = 0.2. We further assumed an equal cluster size.
In our trial, 13 clusters are included and randomized. The
low number of clusters was considered in the sample size
calculation with a specific formula (t-distribution). Data
from a previous large study in the same hospital [22] sug-
gests that the average HADS score in cancer patients is
13, with a standard deviation of 7. This is the expected
mean HADS score in the control arm at t4. With 13 clus-
ters, k = 0.2, α = 0.05, a power of 80%, and n = 400 per
arm, a delta in HADS scores of 5.5 can be identified. If k
should be k = 0.1, a difference of 4.1 can be detected.
Measures to reduce confounding and bias
Potential confounding will be controlled by randomization.
Randomization was completed externally by the Center
for Clinical Trials at University Medical Center Leipzig,
Germany. In order to reduce baseline differences, the
randomization was stratified according to the average fre-
quency of psycho-oncological CL services in the past two
years per department. This information was taken from
the yearly documentation of the CL service.
By using standardized tools and training interviewers,
a potential information bias will be reduced. Moreover,
the study nurses collect data either always on intervention
wards or always on control wards; they do not change trial
arms. The patients are not told to which group they have
been randomized. However, the intervention itself (screen-
ing, consultation with the doctor and referral to the CL
service) obviously cannot be blinded. The results of the
randomization can also not be concealed to the doctors
because they have to change their consultation behavior in
the intervention arm.
Selection bias is intended to be kept to a minimum
through high participation rates. Based on previous ex-
perience [31], we know that highly distressed patients
decline participation disproportionately more often. We
control this effect by documenting the reasons for decline
and then comparing participants and non-participants.
Statistical analysis
The main analysis will compare HADS scores of all pa-
tients at t4 in arm one versus arm two using t-tests. Sub-
sequently, only patients highly distressed at baseline inthe two groups will be compared regarding their HADS
score at t4. Because of the limited number of departments,
complete control for confounding cannot be guaranteed
despite randomization; therefore the following variables
will be subsequently adjusted for in a mixed-model ana-
lysis: sex, age, stage of disease and baseline distress. The
analyses will be done as according to the intention to treat
principle. No interim analyses are planned.
Ethics, data protection and study registration
Ethical approval for this study was obtained from the
Ethics Committee at Leipzig University (reference num-
ber 210-12-02072012). As this is a cluster randomized
trial, patients cannot be asked whether they agree to be
randomized or not. Instead, informed consent is ob-
tained after the patient has been admitted to the ward.
Patients can opt out, that is, they can decide not to take
part in this study. If this is the case, the patient is not
screened for distress and, hence, the following steps of
the stepped care model are not applied. These patients
receive care as usual.
Confidentiality of the data is ensured by using pseudo-
nyms (patient identification numbers) with each question-
naire and data form. No person-identifying information will
be stored together with the medical and patient-reported
outcome data. Patient identification numbers and person-
identifying information (address and telephone number)
are stored separately in a locker, physically unlinked to the
other data. Only the principal investigator and the two
researchers employed in the project have access to the
data. The study has been registered with the Clinical Trials
Register clinicaltrials.gov (identifier: NCT01859429).
Monitoring
The principal investigator (SS) receives monthly written
and oral reports about enrolment and study conduct.
The project manager (HD) monitors data collection on a
daily bases and supervises all study nurses. He trained
the doctors and visits them regularly on the wards to en-
sure that they adhere to the study protocol. They in turn
can address him with any request they might have at any
time. The study nurses are onsite daily at the wards and,
in arm one, ensure that the doctors make use of the
screening results.
Dissemination policy
Trial results will be communicated to the study partici-
pants after data collection has been completed. Each in-
dividual will receive a letter with information about the
study results in a way that is easily understandable for
lay persons. Healthcare professionals and investigators
will be informed via a scientific paper and presentations
at conferences. All collaborators who have participated
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for authorship. A press release will inform the public.
Discussion
Mental health problems not only cause emotional suffer-
ing but also direct and indirect costs related to financial,
social and clinical issues [32,33]. They are related to high
utilization of health services and can even result in in-
creased mortality [1]. This effect is probably due to poor
therapy adherence. A meta-analyses by DiMatteo et al.
[2] showed that patients suffering from clinical depression
tend to fail in their oncological treatment three times
more often than others.
This calls for timely and adequate psychosocial support,
especially as we know that such support is effective [34].
However, not every cancer patient can and must be
treated by a mental health professional. Allocating limited
resources most sensibly and economically is of crucial
importance for our healthcare system to ensure the best
quality of care to as many patients as possible. It is the
hope of STEPPED CARE, that this model is both effective
and efficient and that it can be tested and implemented in
other hospitals as well, if proven to be effective.
Trial status
The trial is ongoing. Patient enrolment has started
(October 2012) and is not yet complete. It is expected
to end in December 2014.
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